Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025
Rhea-AI Summary
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company specializing in hypertension treatments, will release its Q2 2025 financial results on Tuesday, August 12, 2025, after market close. The company will host a conference call at 4:30 p.m. ET the same day.
The company, which focuses on developing medicines for hypertension, hypertensive nephropathy, and obstructive sleep apnea (OSA), will make the earnings call accessible via phone and webcast. Investors can join using domestic (1-877-704-4453) or international (1-201-389-0920) dial-in numbers with conference ID 13754684.
Positive
- None.
Negative
- None.
News Market Reaction – MLYS
In the Aug 5 session, MLYS gained 2.92%, reflecting a moderate positive market reaction. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2025, after the financial markets close on Tuesday, August 12, 2025.
| Tuesday, August 12th @ 4:30 p.m. ET | |
| Domestic: | 1-877-704-4453 |
| International: | 1-201-389-0920 |
| Conference ID: | 13754684 |
| Webcast: | Webcast Link |
A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
Contact:
Investor Relations investorrelations@mineralystx.com
Media Relations
Melyssa Weible
Elixir Health Public Relations
Phone:1-201-723-5805
Email: mweible@elixirhealthpr.com
